Tech Company Financing Transactions
MAP Pharmaceuticals Funding Round
MAP Pharmaceuticals, operating out of Mountain View, secured $25.3 million from Bay City Capital, FirstMark Capital and Skyline Ventures.
Transaction Overview
Company Name
Announced On
1/25/2005
Transaction Type
Venture Equity
Amount
$25,250,000
Round
Series C
Proceeds Purpose
Proceeds from this financing will be used primarily to advance the Phase II clinical development of the company's two lead drug candidates for the treatment of asthma and migraine.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2400 Bayshore Parkway 200
Mountain View, CA 94043
USA
Mountain View, CA 94043
USA
Phone
Website
Email Address
Overview
MAP is currently developing the proprietary Tempo Inhaler platform, a next-generation pressurized metered-dose inhaler (pMDI) that is designed for the pulmonary delivery of respiratory and systemic drug therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Nelson
Chief Financial Officer
Christopher Chai
Chief Scientific Officer
Thomas Armer
VP - Bus. Development
Anastasios Gianakakos
VP - General Counsel
Charlene Friedman
VP - General Counsel
Thomas McCracken
VP - Human Resources
Marco Rosa
VP - Manufacturing
Alan Petro
VP - Operations
Frederick Graff
Browse more venture capital transactions:
Prev: 1/25/2005: Medsphere Systems venture capital transaction
Next: 1/25/2005: Adenosine Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs